Integrated Biologics Discovery Services from Target to IND

Integrated End-To-End Discovery Services

WuXi Biologics offers industry-leading expertise, state-of-the-art facilities, and multiple antibody generation technology platforms for the discovery of novel monoclonal, bispecific and multispecific antibodies, immunocytokines and other biologics. We tailor solutions to best suit your technical and budget requirements to ensure you achieve your key drug development milestones. Our antibody discovery team comprises about 400 highly-trained scientists for the generation, selection, optimization, and characterization of antibodies or other biologic molecules utilizing advanced in vitro and in vivo approaches. We provide one-stop services from concept to IND filing or modular approaches and flexible business models.

Bispecific Antibodies

Phage Display

Antibody Drug Conjugate

Transgenic Rodents

Multispecific Antibodies

Transgenic Rodents

VHH Naïve, Immune & Synthetic Libraries

Advanced Hybridoma

bsAbs using scFv

Single B Cell Cloning

DISCOVERY

CMC DEVELOPMENT

Target (Concept)

Antibody Discovery Lead Optimization & Characterization

IND Filing Support

Target (Concept)

Target Evaluation

Reagent Materials Generation

Bioinformatics and structural biology tools are used to help identify an appropriate target, domain or epitope for antibody generation activities. We offer target evaluation and identification expertise across a wide array of disease areas.

We generate high-quality control antibodies, target proteins, and tool cell lines for immunization, candidate screening and selection, bioassays, and other research purposes. Additional capabilities include: • Protein Engineering • Protein Bioconjugation • Target Cell Line Characterization • Cell Surface Protein Quantification • In-Cell Biotinylation • Protein Analytics and Stability • Assessment • Reagent Labeling

Oncology Immuno-Oncology Neurology Immunology Metabolic Disease

Antibody Discovery

Monoclonal Antibody Discovery

Traditional Hybridoma Approach

Transgenic Platforms

WuXi Biologics has extensive experience in the generation and lead preclinical candidate (PCC) discovery of mAbs from human, mouse, rat, alpaca, and rabbit covering traditional and heavy-chain-only mAbs. We have established multiple core technology platforms including:

OmniAb® Rodent Platform Alloy’s ATX-Gx TM Mice

Advanced Hybridoma-Monoclonal Antibody Technologies

• Hybridoma • Phage display • Single B cell screening